Lophora LPH-5 Phase Ia Safety Trial

Lophora are planning to begin human trials involving their psilocybin formulation, LPH-5, in 2022 with a Phase I study. Lophora hopes to use LPH-5 to in the treatment of treatment-resistant depression (TRD).

Topic Treatment-Resistant Depression
Compound Psilocybin
Country Denmark
Visit trial
Status Planned
Results Published
Start date 12 March 2022
End date 12 April 2023
Phase Phase I
Design Open
Type Interventional
Generation Second
Participants 30
Sex All
Age 18- 99
Therapy No

Trial Details



Trial Number

Sponsors & Collaborators

Lophora
Lophora is a drug-development start-up developing new rapid-acting drugs for central nervous system diseases including treatment-resistant depression.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.